Alnylam Pharmaceuticals Inc (ALNY.US): Amvuttra Monthly Scripts in September Imply Sales Tracking Inline

Our script analysis shows 3Q26 Amvuttra and total TTR sales tracking inline with consensus. Updated monthly script analysis (Symphony) covering July/August/September indicates 3Q26 US Amvuttra sales of ~$881M, which, combined with our OUS estimate (~$252M; +24% q/q), suggests worldwide Amvuttra sales of ~$1,133M (+12% q/q), inline with consensus of $1,124M (+11% q/q). Accounting for our WW Onpattro estimate (~$19M), our analysis implies WW 3Q26 TTR sales of $1,152M (+12%), inline with consensus of $1,144M (+11%). Combined with our recent IQVIA sales analysis, 3Q26 WW Amvuttra (~$1,133-1,167M; +12-15%) and WW TTR (~$1,152-1,186M;